Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis Meeting Abstract


Authors: Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; Stein, E. M.; Brunner, A. M.; McMahon, C. M.; Zeidner, J. F.; Savona, M. R.; Stempel, J. M.; Chandhok, N. S.; Ramaswamy, R.; Roboz, G. J.; Rolles, B.; Wang, E. S.; Harris, A. C.; Amaya, M. L.; Hawkins, H.; Grenet, J.; Gurnari, C.; Shallis, R. M.; Xie, Z.; Maciejewski, J. P.; Sallman, D. A.; Della Porta, M. G.; Komrokji, R. S.; Zeidan, A. M.
Abstract Title: Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis
Meeting Title: 65th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 142
Issue: Suppl. 1
Meeting Dates: 2023 Dec 9-12
Meeting Location: San Deigo, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2023-11-02
Start Page: 4613
Language: English
ACCESSION: WOS:001159740308102
DOI: 10.1182/blood-2023-178728
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein